Scarica l'app Stockscreener
12.00
1.88%
-0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$12.23
Aprire:
$12.04
Volume 24 ore:
1.62M
Relative Volume:
1.03
Capitalizzazione di mercato:
$1.34B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-8.5714
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
-10.25%
1M Prestazione:
-18.14%
6M Prestazione:
-33.88%
1 anno Prestazione:
-27.67%
Intervallo 1D:
$11.86
$12.21
Intervallo di 1 settimana:
$11.86
$14.22
Portata 52W:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.00 | 1.37B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
125.80 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.84 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.61 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.42 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.15 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Can momentum traders help lift NovoCure LimitedJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Can NovoCure Limited stock deliver sustainable ROETrade Volume Summary & Fast Exit Strategy with Risk Control - newser.com
NovoCure (NVCR) Is Down 5.7% After Q3 Revenue Growth and Expanded International Coverage — Has the Growth Story Changed? - simplywall.st
Measuring NovoCure Limited’s beta against major indicesPrice Action & Reliable Volume Spike Trade Alerts - newser.com
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
Chart overlay techniques for tracking NovoCure LimitedQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
How to recover losses in NovoCure Limited stockQuarterly Market Summary & Stepwise Entry/Exit Trade Alerts - newser.com
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
Is NovoCure Limited stock attractive for hedge fundsGDP Growth & Pattern Based Trade Signal System - newser.com
Is NovoCure Limited stock oversold or undervaluedGap Up & Weekly Momentum Stock Picks - newser.com
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Q3 2025 Earnings Call Transcript - Insider Monkey
How interest rate cuts could boost NovoCure Limited stockStock Surge & Weekly High Return Stock Opportunities - newser.com
What does recent volatility data suggest for NovoCure LimitedJuly 2025 Reactions & Consistent Profit Trade Alerts - newser.com
NovoCure’s Mixed Q3: Growth Amid Challenges - TipRanks
NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st
NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results - MarketBeat
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
NovoCure: Q3 Earnings Snapshot - Stamford Advocate
Novocure Ltd earnings beat by $0.09, revenue topped estimates - Investing.com UK
Emerald Mutual Fund Advisers Trust Reduces Position in NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges - Yahoo Finance
NovoCure Expands Global Reach Within Nasdaq Today Trends - Kalkine Media
Novocure Ltd. Reports Q3 2025 Financial Results - TipRanks
Order flow analysis tools used on NovoCure Limited2025 Top Decliners & AI Driven Price Predictions - newser.com
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | N - GuruFocus
Assessing NovoCure (NVCR) Valuation as Investors Revisit Recovery Potential - simplywall.st
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance
Novocure’s Revenue Beats Forecasts As Cancer Pipeline Expands - Finimize
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Novocure (NVCR) Exceeds Q3 Revenue Expectations with Strong Grow - GuruFocus
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Emerald Advisers LLC Lowers Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus
Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy - Stock Titan
Can NovoCure Limited hit a new high this monthJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
NovoCure (NASDAQ:NVCR) Given New $23.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Real time breakdown of NovoCure Limited stock performanceWeekly Risk Summary & Weekly Setup with High ROI Potential - newser.com
Is NovoCure Limited stock a safe investment in uncertain marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why NovoCure Limited stock remains undervaluedQuarterly Earnings Report & High Accuracy Trade Alerts - newser.com
Will NovoCure Limited stock attract more institutional investorsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
Detecting support and resistance levels for NovoCure LimitedJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Is NovoCure Limited (038) stock testing key supportJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - newser.com
NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Will NovoCure Limited (038) stock profit from automation waveMarket Movement Recap & Expert Verified Stock Movement Alerts - fcp.pa.gov.br
JP Morgan Maintains NovoCure (NVCR) Neutral Recommendation - Nasdaq
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - TipRanks
Will NovoCure Limited stock outperform growth indexes2025 Top Decliners & Low Risk Entry Point Guides - fcp.pa.gov.br
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment - TipRanks
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):